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Allogeneic stem cell transplant (SCT) after high-dose conditioning with BEAM/ﬂudarabine/total body irra-
diation (TBI) in patients with relapsed or refractory lymphoma has shown promising results in a pilot study.
In this trial, we treated 50 consecutive patients with refractory or relapsed lymphoma or chronic lymphocytic
leukemia (CLL). The patients included were considered to have poor-prognosis disease (eg, one-third was
chemo-refractory at transplantation and more than one-half had failed previous autologous or allogeneic
SCT). All patients engrafted and achieved full donor chimerism. Grade II-IV acute graft-versus-host disease
(aGVHD) occurred in 64% of patients (95% conﬁdence interval [CI], 52% to 79%), and chronic GVHD (cGVHD) in
51% (95% CI, 36% to 66%). At 3 years, overall survival was 61% (95% CI, 46% to 75%). Progression-free survival
was 55% (95% CI, 40% to 70%), with 30% (95% CI, 19% to 47%) transplantation-related mortality and a relapse
incidence of 15% (95% CI, 7% to 32%). Disease classiﬁcation and stage as well as remission status at trans-
plantation and type of previous treatment (including previous SCT) had no signiﬁcant impact on trans-
plantation outcome. In conclusion, allogeneic SCT after BEAM/ﬂudarabine/TBI provides excellent tumor
control with complete and durable remissions in patients with poor-prognosis lymphoma and CLL. High rates
of GVHD and GVHD-related mortality associated with this regimen are a major concern and warrant modi-
ﬁcation of the regimen in the future.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy followed by autologous stem
cell transplant (SCT) is the standard of care for lymphoma
that has relapsed or is refractory to standard treatment [1].
Although curative in some cases, many patients still relapse
after auto-SCT. In this situation, allogeneic SCT can provide
a further rescue option [2]. Compared to autologous trans-
plantation, allogeneic SCT holds the advantage of avoiding
tumor cell contamination of the graft, provides a graft-
versus-lymphoma effect, and offers the possibility of trans-
plantation in case of autologous stem cell mobilization
failure plus the possibility of donor lymphocyte infusion in
event of insufﬁcient tumor control [3,4].
The curative potential of allogeneic SCT has been
demonstrated for the complete spectrum of lymphoid
neoplasms including chronic lymphocytic leukemia (CLL),
follicular non-Hodgkin lymphoma (NHL), aggressive NHL,
Hodgkin’s lymphoma (HL), and T-cell lymphoma [5-10].
Many controversies exist as to which patients should be
offered allogeneic SCT, as well as to their proper assignment
to the different myeloablative and reduced-intensity condi-
tioning (RIC) regimens at hand [11]. Myeloablative condi-
tioning regimens generally provide, at the cost of higher
treatment-relatedmortality (TRM), improved disease control
with relapse rates of less than 20%. In contrast, RIC allogeneicedgments on page 85.
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increased relapse rates [12].
We have previously reported on our experience of allo-
geneic SCT after conditioning with BEAM/ﬂudarabine/total
body irradiation (TBI) in 11 patients with lymphoma, an
approach designed to combine the cytoreductive properties
of the BEAM regimen with the graft-versus-tumor effect of
allogeneic transplantation [13]. In this study, we present the
ﬁnal evaluation of 50 consecutive patients with poor prog-
nosis lymphoma or CLL treated with this regimen.
MATERIALS AND METHODS
Treatment Plan
The conditioning regimen consisted of etoposide dose-intensiﬁed BEAM
chemotherapy (BCNU 300 mg/m2 i.v. once daily on day 5, etoposide 200
mg/m2 i.v. twice daily on days 5 to 2, cytarabine 200 mg/m2 i.v. twice
daily on days 5 to2, and melphalan 140 mg/m2 i.v. once daily on day1)
with overlapping ﬂudarabine 30 mg/m2 given once daily on days 4 to 2.
This was followed by a single dose of TBI (2 Gy) on the day of stem cell
infusion. All patients gave written informed consent to their treatment and
to having their data analyzed.
GVHD Prophylaxis and Supportive Care
Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine
and a short course of mycophenolate mofetil (MMF) until day 28 (continued
in the case of active GVHD) [13]. Trough cyclosporine target level was 200
ng/mL and was quantiﬁed at least once a week. MMF levels were not
measured. In the absence of GVHD, cyclosporine was tapered by day 180.
All patients were treated in reverse protective isolation and received
prophylaxis with valacyclovir 500 mg twice daily, ﬂuconazole 400 mg once
weekly, and co-trimoxazole 3 times a week. In the event of fever, broad-
spectrum antibiotics and, when necessary, antifungal medication or ganci-
clovir were prescribed. Irradiated and leucodepleted blood products were
administered in order to maintain a hemoglobin level above 80 g/L and
platelet counts above 10 G/L. Local cryotherapy to reduce mucositis or
growth factor support were not given. No peritransplantation rituximabwasTransplantation.
Table 1
Patient and Transplant Characteristics
Variables N (Range)
No. of patients 50
Age, median (range) 49 (22-64)
Male/female 28/22
Comorbidities
Sorror score 0 24
Sorror score 1-2 17
Sorror score 3 9
Donor
HLA-identical sibling 29
HLA-matched unrelated 19
HLA-1 antigen mismatched unrelated 2
Disease characteristics according to histology
 Follicular NHL (no.) 8
Initial risk score intermediate to high (FLIPI) 7
Median no. of prior chemotherapy lines (range) 6 (4-7)
Prior SCT 6
Chemorefractory disease at transplantation 3
 CLL (no.) 13
Cytogenetics del17p 5
Cytogenetics del11q 3
Median no. of prior chemotherapy lines 2 (1-5)
Chemorefractory disease at transplantation 5
 Diffuse large B cell lymphoma (no.) 8
Initial risk score intermediate to high (IPI) 7
Median no. of prior chemotherapy lines 5 (1-8)
Prior SCT 7
Chemorefractory disease at transplantation 2
 Mantle cell lymphoma (no.) 5
Initial risk score intermediate to high (MIPI) 4
Median no. of prior chemotherapy lines 2 (1-3)
Prior SCT 1
Chemorefractory disease at transplantation 1
 HL (no.) 8
Median no. of prior chemotherapy lines 6.5 (5-8)
Prior SCT 7
Chemorefractory disease at transplantation 3
 Peripheral T-cell lymphoma 6
Median no. of prior chemotherapy lines 3.5 (2-6)
Prior SCT 3
Chemorefractory disease at transplantation 1
 Others 2
Median no. of prior chemotherapy lines 4.5
Prior SCT 0
Chemorefractory disease at transplantation 1
NHL indicates non-Hodgkin lymphoma; FLIPI, Follicular Lymphoma Inter-
national Prognostic Index; SCT, stem cell transplant; CLL, chronic lympho-
cytic leukemia; IPI, International Prognostic Index; MIPI, MCL International
Prognostic Index; HL, Hodgkin’s lymphoma.
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treatment within 3 months before allo-SCT was recorded in 15 patients.
Endpoints
The primary endpoint was progression-free survival (PFS). Secondary
endpoints consisted of overall survival (OS), transplant-related mortality,
relapse incidence, engraftment, and regimen-related toxicity. Toxicity was
graded according to the National Cancer Institute Common Terminology
Criteria for Adverse Events version 3.0. Severity of acute GVHD (aGVHD) and
chronic GVHD (cGVHD) was rated as deﬁned by the revised Glucksberg
criteria and the National Institutes of Health consensus [14,15]. Response
was assessed according to current and standardized criteria [16-19]. As
previously described in the setting of myeloid neoplasms, we calculated the
comorbidity risk index according to Sorror et al. [20]. Risk stratiﬁcation at
diagnosis of diffuse large B cell lymphoma (International Prognostic Index),
follicular NHL (Follicular Lymphoma International Prognostic Index), and
mantle cell lymphoma (MCL International Prognostic Index) was derived
from the respective scoring systems [21-23]. “Histologically aggressive”
disease included diffuse large B cell lymphoma, blastoid variant mantle cell
lymphoma, peripheral T cell lymphoma, or grade 3 follicular lymphoma,
whereas the remaining cases of NHL were classiﬁed as “histologically
nonaggressive.”
Statistical Analysis
OS and PFS were estimated by Kaplan-Meier analysis. Cumulative inci-
dence rates of relapse and TRM were calculated by treating these events ascompeting outcomes. Variables affecting OS were analyzed in a multivari-
able fashion using Cox models, with aGVHD and cGVHD incorporated as
time-dependent covariates.RESULTS
Between 2002 and 2011, 28 male and 22 female patients
ages 22 to 64 (median, 49 years) received protocol treatment
for poor prognosis lymphoma. Patients had refractory or
relapsed CLL (n ¼ 13), HL (n ¼ 8), or NHL (n ¼ 29). The
median time from initial diagnosis to transplantation was 46
months (range, 5-180 months). Patients had undergone
a median of 5 previous treatment lines (range, 1-8),
including autologous SCT after BEAM conditioning in 44%.
Eight of the patients experienced early relapse after
autologous SCT (<6 months postautograft). Five patients had
undergone previous allogeneic SCT after RIC. Disease status
at transplantation was progressive in 16%, stable disease in
16%, partial remission (PR) in 42%, and complete remission
(CR) in 26%. This collective of 50 patients includes 9 patients
who were part of our preliminary report in 2007 [13].
Further patient and disease characteristics are shown in
Table 1.
Stem cell donors were either HLA-identical siblings (58%),
10/10 HLA-matched unrelated donor (38%) or 9/10 matched
unrelated (4%). Stem cell source was bone marrow in 2
matched unrelated donor transplantations, and granulocyte
colony-stimulating factoremobilized peripheral blood in all
remaining cases. The median CD34þ cell count infused
amounted to 6.5  106 cells/kg.Engraftment, GVHD, and Regimen-Related Toxicity
All evaluable patients engrafted after a median of 12 days
(range, 9-27 days) and achieved full donor chimerism on
day þ30. The median hospitalization length was 34 days
(range, 23-231 days). Nopatient received posttransplantation
donor lymphocyte infusions. AGVHD occurred in 38 of the 50
patients (76%): grade I in 6 (12%), grade II in 10 (20%), grade III
in 11 (22%), and grade IV in 11 (22%). Interestingly, 2 patients
developed aGVHD after MMF discontinuation. Of the 41
patients surviving past day 100, 21 (51%) developed cGVHD
(10 limited/11 extensive). GVHD was the primary cause of
death in 10 patients.
Major TRM resulted from mucositis and infection in
neutropenia. Neutropenic fever occurred in all patients and
was treated with broad-spectrum antibiotics. Blood cultures
were positive for coagulase-negative staphylococcus in 3
patients, enterococcus faecium in 2 patients, and pseudo-
monas aeruginosa in 1 patient. Extended-spectrum beta-
lactamase Escherichia coli and Candida glabrata septicemia
both occurred once. Invasive fungal infection of the lungs
was diagnosed in 14 patients (9 possible, 3 probable, and 2
proven cases). Viral infections were documented in 5
patients (cytomegalovirus), 2 patients (respiratory syncytial
virus), and 1 patient (norovirus) in the ﬁrst month post-
transplantation, respectively. Infection was the primary
cause of death in 4 patients.
Mucositis was observed in all patients: severity was grade
4 in 62%, grade 3 in 30%, and grade 2 in 8% of patients. The
correlation with pretransplantation renal function did not
reach statistical signiﬁcance. Severe bleeding complications
(grade 3) were diagnosed in 3 patients. Two cases of diffuse
alveolar hemorrhage resolved under high-dose steroid
treatment, whereas cerebral hemorrhage led to the death of
1 patient.
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Figure 1. Progression-free survival (PFS), treatment-related mortality (TRM),
and relapse incidence of 50 patients with advanced lymphoma treated with
allogeneic HSCT after conditioning with BEAM/ﬂudarabine/TBI.
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By day 30, 1 patient (2%) had died of treatment-related
complications. Of the remaining patients, 88% were in CR,
10% in PR, and 2% had a stable disease status at day 30. The
patient with stable disease reached a CR without further
therapy 3 months posttransplantation. As for the patients in
PR at day 30, 1 died of GVHD shortly thereafter; 2 achieved
CR without further therapy at 6 months and 2 years post-
transplantation, respectively; 1 achieved CR after a subse-
quent cycle of chemotherapy; and 1 patient remains in
a stable PR at 4 years of observation.OS and PFS
With a median follow-up of 3.4 years, 30 patients (60%)
were alive at last data collection. Kaplan-Meier estimated
PFS at 3 years was 55% (95% conﬁdence interval [CI], 40-70
40% to 70%), with 30% (95% CI, 19% to 47% 19-47) TRM, and
a relapse incidence of 15% (95% CI, 7% to 32%, Figure 1).
Three-year OS rate was 61% (95% CI, 46% to 75%). Fifteen
patients (30%) died of TRM. The cause of treatment-associ-
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Figure 2. Overall survival in patients stratiﬁed according to disease stage at transplan
(P ¼ .05) (B); and by disease histology (CLL, chronic lymphocytic leukemia; P ¼ .69)and cerebral hemorrhage in 1 patient, as described above. At
last follow-up, 5 patients (10%) had died of relapse. In 1
patient with CLL, remission was only partial but has been
maintained for over 5 years.
To analyze further the impact of disease characteristics
on transplantation outcome, we used a multivariable Cox
model. The development of aGVHD grade II-IV strongly
correlated with a poor outcome (hazard ratio [HR], 10.1, 95%
CI, 2.16-47.7, P ¼ .003), whereas development of cGVHD
showed a protective effect, which did not reach the level of
statistical signiﬁcance. Notably, remission status at trans-
plantation had no signiﬁcant impact on the success of the
transplantation procedure in either multivariate or univar-
iate analysis (Figure 2A). Similarly, a history of failed
autologous transplantation had no detrimental effect on OS
(5-year OS rates of 57% and 47% for patients with andwithout
previous autologous transplantation, P ¼ .20).
There was a trend toward poorer survival for recipients of
unrelated donor compared to sibling donor allografts
(multivariable HR 2.21, P ¼ .12; univariate 3 year OS 40%
versus 74%, P ¼ .05, Figure 2B). When patients were grouped
according to histology, no signiﬁcant differences in OS were
noted, although the number of patients in each group was
small (N¼ 5-23, P¼ .69, Figure 2C). In Coxmodeling, patients
with histologically aggressive disease showed a trend toward
worse outcome (Table 2). In accordance with previous
studies, development of aGVHD had a detrimental effect on
survival, whereas cGVHD was found to be protective.
DISCUSSION
Relapse and progression of lymphoma and CLL after both
standard and high-dose chemotherapy are common [24,25].
In such cases, prognosis is poor and there is no optimal
strategy established. Allogeneic SCT is potentially curative in
this situation [26]. However, opinions are split on which
patients should be offered allogeneic SCT. Recommendations
further diverge onwhich conditioning regimen to use and on
what intensity it should bear. After myeloablative condi-
tioning regimens, relapse rates of less than 20% have been
documented, although at the cost of high TRM rates of up to
65% [27,28]. Reduced-intensity protocols demonstrate lower
treatment-associated mortality, but relapse rates seem to be
higher than after myeloablative regimens [29-31]. The
cytostatic constituents of the conditioning regimen vary,
frequently including ﬂudarabine, TBI, or busulfan combined
with cytarabine or melphalan [5,32,33].Sibling donor
Unrelated donor
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t (CR, complete remission; PR, partial remission; P ¼ .85) (A); by the donor type
(C).
Table 2
Factors Affecting Overall Survival in Cox Analysis
Risk Factor HR 95% CI P value
Response status at transplant
CR 1.00 - -
PR 0.73 0.21-2.46 .61
Refractory/untreated relapse 0.75 0.24-2.32 .62
Donor type
Unrelated versus related 2.21 0.81-6.03 .12
Histology
Aggressive versus indolent 2.75 0.96-7.85 .06
aGVHD*
Grade II-IV versus 0-I 8.97 1.92-42.1 .005
cGVHD*
Present 0.53 0.14-1.91 .33
HR indicates hazard ratio; CI, conﬁdence interval; CR, complete remission;
PR, partial remission; aGVHD, acute graft-versus-host disease; cGVHD,
chronic graft-versus-host disease.
* Coded as time-dependent covariables.
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toxicity as a conditioning regimen for the autografting and
allografting of lymphoproliferative malignancies [34-38]. As
mixed chimerism was reported after conditioning with
BEAM and alemtuzumab [39], we supplemented etoposide
dose-intensiﬁed BEAM chemotherapy with 3 days of ﬂu-
darabine and a 2 Gy dose of TBI [13], based on data that
the combination of ﬂudarabine and TBI allows consistent
engraftment without adding substantial toxicity [40]. This
combination was historically established in a protocol in
which BEAM chemotherapy without stem cell support was
followed 28 days later by ﬂudarabine/TBI and allogeneic SCT
[41]. Because of high infectious morbidity associated with
the prolonged aplasia in this protocol, the regimen was
condensed with BEAM and ﬂudarabine being administered
in parallel and immediately followed by TBI and SCT.
In this set of 50 patients with poor-risk lymphoma or CLL,
high remission rates and a low incidence of relapse were
achieved. Importantly, the regimen produced long-term
survival in otherwise ill-fated patients such as those expe-
riencing relapse after a previous BEAM/autograft procedure.
This fact, along with several patients in this cohort convert-
ing to CR during follow-up, demonstrates the importance of
the graft-versus-tumor effect in this approach. Further
support for this comes from the reduced relapse risk and
improved survival in patients experiencing cGVHD, although
relapse rates were overall too low for these associations to
reach the level of statistical signiﬁcance.
A previous multicenter trial performed allogeneic trans-
plantation after a conditioning regimen combining BEAM
with the anti-CD52 Ab alemtuzumab [39]. Although the
addition of alemtuzumab effectively prevented GVHD
grade >II, a substantial portion of patients experienced
either primary graft failure or developed mixed chimerism,
necessitating the administration of donor lymphocyte infu-
sion. Furthermore, outcome of the high-risk subgroup of
patients with a relapse after previous autologous SCT was
poor in this study, suggesting that BEAM/alemtuzumab
might be an optimal choice for patients with a lower risk of
relapse. We found the BEAM/ﬂudarabine/TBI regimen to be
effective in patients at high risk of relapse with active disease
at transplantation, regardless of disease histology or of
a history of prior failed autograft. Unfortunately, deﬁnitive
conclusions on predictive factors cannot be drawn because of
the sample size and study design.
Although introducing allogeneic SCT into clinical courses
that failed to remit under conventional treatment allowedmore than one-half of the patients to attain long-term
survival, 30% died of TRM. AGVHD led to death in 10 patients,
followed by infection as the cause of death in 4 patients. The
rate of GVHD as well as mucositis incidence and severity
were signiﬁcantly higher when compared to those reported
after similar BEAM-based protocols [39,42]. We believe that
etoposide dose-intensiﬁcation, radiation-induced mucous
membrane injury, plus a drug interaction between ﬂudar-
abine and melphalan, may have all increased the incidence
and severity of mucositis in our protocol [43-45].
To reduce the incidence of GVHD, higher MMF dosages
and a delayed tapering starting on day 40 with a targeted
stop on day 96, as endorsed by the Seattle trials, should
permit us to diminish the GVHD occurrence in unrelated SCT
[46]. Following the results published by Finke et al. [47], we
are now also supplementing unrelated SCT with polyclonal
anti-T cell globulin infusions in a further attempt to reduce
the incidence of aGVHD. However, this measure will atten-
uate the graft-versus-tumor effect and may thereby raise the
risk of recurrences. We believe that the comparatively low
relapse rates observed in this series should allow for this
sanction and for a reduction of the conditioning intensity (eg,
by omission of TBI and a cutback in the etoposide dose-
intensiﬁcation in order to also diminish mucosal toxicity).
In conclusion, allogeneic SCT after BEAM/ﬂudarabine/TBI
provides excellent disease control in patients with poor-
prognosis lymphoma or CLL. The regimen seems to overcome
prognostic markers traditionally associated with poor
outcome such as active disease at transplantation and history
of failed autograft, making it particularly suitable for the
treatment of high-risk patients. However, the high rate of
TRM mainly due to aGVHD calls for further modiﬁcation of
the regimen.ACKNOWLEDGMENTS
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